View Older Stories View More Recent Stories
-
Phio Pharmaceuticals signs manufacturing deal for PH-762 drug substance
-
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
-
H.C. Wainwright Reiterates Buy Rating on Phio Pharma (PHIO)
-
Phio Pharmaceuticals Corp. (PHIO) Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
-
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
-
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Corp. (PHIO) Announces Strategic Initiative to Create Awareness of the INTASYL siRNA Portfolio
-
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
-
H.C. Wainwright Assumes Phio Pharma (PHIO) at Buy
-
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
-
Phio Pharmaceuticals Corp. (PHIO) Misses Q1 EPS by 41c
-
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
-
Phio Pharmaceuticals (PHIO) Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
-
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
-
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Corp. (PHIO) Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
-
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
-
H.C. Wainwright Reiterates Buy Rating on Phio Pharma (PHIO)
-
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
-
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
-
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
-
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
-
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Corp. (PHIO) Appoints David H. Deming to its Board
-
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
-
H.C. Wainwright Reiterates Buy Rating on Phio Pharma (PHIO)
-
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Corp. (PHIO) Files for 5.93M Share Offering by Selling Stockholders
-
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Prices 833.3K Share Offering at $3/sh
-
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Announces 1.06M Share Offering at $3/sh
-
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Reports Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
-
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
-
Phio Pharmaceuticals Corp. (PHIO) Announces Publication in Clinical, Cosmetic and Investigational Dermatology
-
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
-
Phio Pharmaceuticals Corp. (PHIO) Prices 240K Share Offering at $2/sh
-
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
-
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
-
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology
-
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
-
Phio Pharmaceuticals Corp. (PHIO) Tops Q3 EPS by 260c
-
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
